

Worldwide experience of breast implant-associated large cell lymphoma (BIA-ALCL): Expert panel and roundtable discussion

Author

Kenkel, Jeffrey M, Magnusson, Mark, Mercer, Nigel SG, Adams, William P

Published

2019

Journal Title

Aesthetic Surgery Journal Open Forum

DOI

[10.1093/asjof/ojz020](https://doi.org/10.1093/asjof/ojz020)

Rights statement

© 2019 The American Society for Aesthetic Plastic Surgery, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from

<http://hdl.handle.net/10072/405817>

Griffith Research Online

<https://research-repository.griffith.edu.au>



Worldwide Experience of Breast Implant-Associated Large Cell Lymphoma (BIA-ALCL): Expert Panel and Roundtable Discussion

Jeffrey M. Kenkel, MD, FACS; Mark Magnusson, MBBS, FRACS; Nigel S. G. Mercer, ChM, FRCS, FRCPC, FFFMLM; and William P. Adams Jr, MD

Aesthetic Surgery Journal
Open Forum
2019, 1–2

© 2019 The American Society for Aesthetic Plastic Surgery, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1093/asjof/ojz020
www.asjopenforum.com

OXFORD
UNIVERSITY PRESS

Editorial Decision date: July 5, 2019; online publish-ahead-of-print July 18, 2019.

We are pleased to present this roundtable discussion, recorded live at The Aesthetic Meeting 2019 in New Orleans, featuring the most up-to-date, evidence-based knowledge on breast implant-associated large cell lymphoma (BIA-ALCL) from a panel of worldwide experts (a transcript of the discussion is available online as [Supplemental Material](#) at www.asjopenforum.com). The panelists share updates on the entity from their region and also their experience with BIA-ALCL. The panelists have been published extensively on this subject¹⁻⁶ and were selected for their expertise, worldwide perspective,

and history of patient safety advocacy. It's important to note that research in this field is rapidly evolving⁷ and we encourage you to stay current by reading the journals in our field and attending meetings featuring BIA-ALCL panels and discussions.

Supplementary Material

This article contains supplementary material located online at www.asjopenforum.com.



Video. Watch now at <https://academic.oup.com/asjopenforum/article-lookup/doi/10.1093/asjof/ojz020>

Dr Kenkel is a Professor and Chair, Department of Plastic Surgery, UT Southwestern Medical Center, Dallas, TX; and is Associate Editor of the *Aesthetic Surgery Journal (ASJ)* and *ASJ Open Forum*. Dr Magnusson is an Associate Professor, Griffith University, Southport, Queensland, Australia. Dr Mercer is a plastic surgeon in private practice in Bristol, UK. Dr Adams is an Associate Professor, Department of Plastic Surgery, and Program Director of the Aesthetic Surgery Fellowship at UTSW, University of Texas Southwestern, Dallas, TX.

Corresponding Author:

Dr Jeffrey M. Kenkel, Department of Plastic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390–9132, USA,

E-mail: jeffrey.kenkel@utsouthwestern.edu; Twitter: [@drkenkel](https://twitter.com/drkenkel)

Disclosures

Dr Kenkel received an educational grant from Galderma for the anatomic laboratory; and research grants from Bellus Medical and Venus Concept. Dr Magnusson received no funding support for this presentation; however, he is a current advisor to Allergan and has a past educational association with Mentor. Mr Mercer was a member of the Allergan Expert Forum from 2011 to 2012. Dr Adams declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

The authors received no financial support for the research, authorship, and publication of this article.

REFERENCES

1. Mercer NSG. Perspective from the United Kingdom on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). *Aesthet Surg J Open Forum*. 2019;1(1): doi: 10.1093/asjof/ojz003
2. Deva AK, Cuss A, Magnusson M, Cooter R. The “game of implants”: a perspective on the crisis-prone history of breast implants. *Aesthet Surg J*. 2019;39(Supplement_1):S55-S65.
3. Magnusson M, Beath K, Cooter R, et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. *Plast Reconstr Surg*. 2019;143(5):1285-1292.
4. Kadin ME, Deva A, Xu H. Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J*. 2016;36(7):773-81.
5. Sieber DA, Adams WP Jr. What’s your micromort? A patient-oriented analysis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). *Aesthet Surg J*. 2017;37(8):887-891.
6. Jewell M, Spear SL, Largent J, Oefelein MG, Adams WP Jr. Anaplastic large T-cell lymphoma and breast implants: a review of the literature. *Plast Reconstr Surg*. 2011;128(3):651-61.
7. Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). *Aesthet Surg J*. 2019;39(Supplement_1):S3-S13.